Clinical intelligence that turns patient data into regulatory-grade evidence.
AppMed™ is a Health Canada-approved SaMD Class II platform transforming clinical care through continuous monitoring, precision dosing, and real-world evidence generation. Join us at the intersection of data and clinical outcomes.
The Team
Built by Leaders Across Medecine, Law, Engineering ,and Finance
A multidisciplinary founding team with deep roots in clinical research, regulatory affairs, software engineering, and healthcare finance, united by a shared belief in the power of data-driven medicine.
Martin Noël, PhD, MHA
Chief Executive Officer
Accomplished leader with global expertise in medical affairs, drug development, clinical research, and commercialization across multiple therapeutic areas, including oncology, cardiology, gene therapy, and infectious diseases.
Proven success in business development, licensing, regulatory negotiation, and market access, coupled with a strong foundation in academia and stakeholder engagement.
Danièle Milette, M.Fisc
Chief Financial Officer
A seasoned tax professional with extensive experience in leading professional firms, specializing in technology companies.
Provides strategic and financial guidance to businesses, particularly start-ups, and holds positions on multiple boards of directors. An active investor for nearly a decade and a dedicated member of the Anges Québec network.
Louis-Paul Marin, Eng., LL.B., LL.M.
Founder, Chairman of the Board
Dual-qualified in engineering and law, Me Marin brings a distinctive ability to navigate the complex, highly regulated medical device sector. His combined technical and legal expertise provides a deep understanding of product design, manufacturing, quality systems, and evolving regulatory frameworks.
Committed to ethical practices and patient safety, Louis-Paul leverages this foundation to drive innovation while ensuring compliance, enabling life-saving technologies to reach patients efficiently and responsibly.
Gilles Pelletier, M.Eng., MBA
Co-founder, Chief Technical Officer
Senior consultant in software verification and validation, Gilles has supported organizations ranging from startups to established industry leaders in developing software for medical devices. He brings deep expertise in implementing development processes aligned with regulatory standards.
He has built and led teams of over 40 engineers and software scientists, and has held senior leadership roles overseeing engineering and operations in Air Traffic Control.
Regulatory & IP Foundation
Built on a Defensible Foundation of Standards, Approvals & Patents
AppMed™ is engineered to international medical-device standards, approved by Health Canada, and protected by granted patents in Canada and the US, giving partners and investors a regulatory and IP moat that’s hard to replicate.
International Standards
Validated to Global Medical Device Standards
AppMed™ is built in conformance with the international standards referenced by Health Canada, the FDA, and European regulators for Software as a Medical Device.
IEC 62304 Medical device software life-cycle processes
IEC 62366 Usability engineering for medical devices
ISO 14971 Risk management for medical devices
Regulatory Approval
Approved by Health Canada
AppMed™ holds an active Health Canada Medical Device License as a Class II instrument, a defensible regulatory foundation for clinical deployment across Canadian healthcare institutions.
Product License
Actively Maintained · Audit-Ready
Intellectual Property
Patent-Protected Technology
Core methodologies are protected by granted patents in two major jurisdictions, with additional IP filings in progress, creating a durable competitive moat across precision dosing and therapeutic drug monitoring.
Actively Maintained · Audit-Ready
Granted: “System and Method for Identifying Optimal Posology for an Individual“
US Provisional Patent — Filed: “Method for Monitoring Exposure to Therapeutic Drugs with the use of an In Vitro / In Silico Correlationl“
3
International Standards
2
PAtents granted (CND + US)
1
Health Canada Class II License
1
Provisional Patent Filled
Competitive Positioning
Why AppMed™ Wins Where Others Can't Follow
Most clinical data platforms cover one piece of the puzzle. AppMed™ combines regulatory approval, patented methodology, integrated microsampling, and Canadian data sovereignty into a single deployment, a moat that takes years (and patents) to replicate.
See the full competitive analysis in our investor deck.
Market Opportunity
A $43B Global Opportunity Underserved by Continuous Clinical Intelligence
The global real-world evidence and digital therapeutics markets are converging into a $43B opportunity by 2030, driven by regulatory pressure, healthcare cost optimization, and demand for continuous real-world evidence in drug development.
$43B
TAM — Global Opportunity by 2030
Combined global real-world evidence ($10.8B) and digital therapeutics ($32.5B) markets by 2030. Sources: MarketsandMarkets 2024; Grand View Research 2024.
Sources: Grand View Research 2024.
$1.5B
SOM — 3-Year Reachable Revenue
RWE-addressable segment serving specialty therapeutics across Canada & the US, derived from North America RWE market (~$3.5B) scoped to specialty/oncology use cases.
Source: Grand View Research, 2025.
$20M
Total annual investment
Canada captures ~$1.6B in annual pharmaceutical clinical trial investment, with significant opportunity to optimize data capture, efficiency, and real-world evidence generation. Observed across clinical partners using continuous remote monitoring capabilities.
Source: Innovative Medicines Canada, 2024.
$1.6B
Total annual investment
Canada captures ~$1.6B in annual pharmaceutical clinical trial investment, with significant opportunity to optimize data capture, efficiency, and real-world evidence generation. Observed across clinical partners using continuous remote monitoring capabilities. Source: Innovative Medicines Canada, 2024.
Source: Innovative Medicines Canada, 2024.
Traction
Deployed, Enrolling, and Generating Revenue
Four active clinical pilots across pediatric surgery, adherence research, and pain management · a signed letter of intent with an LSPQ-certified diagnostic lab · exclusive Canadian distribution rights already producing recurring revenue. AppMed™ is not a concept — it is in the field.
Hormonova
Clinical pilot – in progress
Real-world validation of AppMed’s dosing optimization and adherence platform inside Hormonova’s clinical workflow.
LUPIN study
50 Patients
Pediatric Tonsil Surgery At-Home Recovery Study. Evaluating post-operative care tracking and parent-administered medication adherence in a pediatric surgical population.
ORDAS trial
90 Patients
Optimizing Research Data Acquisition with Smart Pill Bottles, a feasibility and implementation study for real-time adherence capture in research environments.
ORDAS trial
150 Patients
Largest planned deployment to date. Pain management and medication deprescription pilot rolling out across Beam’s radiology network.
Spina FX Medical Inc.
90 Patients
Safety and Performance of the Triojection® System of Disc Nucleolysis Using Ozone for Treatment of Lumbar Disc Herniation – A Retrospective-Prospective Real-World Study.
C3i Diagnostic Partnership
LSPQ-certified clinical laboratory
Canadian research centers
Closed-loop diagnostic workflow
Sample → analysis → validated result — end to end under one regulatory umbrella.
Signed mutual letter of intent to integrate AppMed’s micro-sampling device with C3i’s certified biomarker workflow. C3i will receive and process AppMed-collected blood samples, perform biomarker analyses under LSPQ clinical laboratory standards, and deliver medically validated diagnostic results reviewed by certified biochemists, in full regulatory compliance.
C3i Diagnostic Partnership
Exclusive Canadian distributor
20+
Canadian research centers
Active commercial channel — live today.
AppMed holds exclusive Canadian distribution rights for Neoteryx’s validated micro-sampling technology — today serving 20+ research institutions across Canada with an active recurring-revenue book. Proof that the commercial channel is already open.
WHAT OUR CLINICAL PARTNERS SAY
Trusted by the
by the Clinicians
Running Our Pilot
Real voices from the frontlines of our active clinical pilots
AppMed™ has the potential to significantly improve our pediatric tonsillectomy recovery protocol. The at-home monitoring platform captures pain scores, medication intake, and recovery markers digitally in real time, streamlining the process compared to traditional paper diaries or phone follow-ups. Our nursing team could potentially identify complications earlier, and we expect families to feel better supported after discharge. We are excited to launch the quality assessment program with our first cohort and intend to implement AppMed™ as a routine clinical tool in our department.
Dr. Chantal Frigon
Montreal Children’s Hospital
AppMed™ is used as a PRO (patient-reported outcome) tool in the clinical setting, facilitating patient data acquisition. Combined with their medication dispensing system, it will better support the trial and the evaluation of our clinical hypotheses. Initial feedback from our first patients has been excellent, the implementation process was seamless thanks to AppMed™ outstanding support.
Dr. Pascal Laferrière-Langlois
Hôpital Maisonneuve-Rosemont
Ecosystem
Our Academic and Private Partners
AppMed™ is trusted by leading Canadian academic medical centres and specialty clinics to generate real-world clinical evidence at scale. Our partners include Université de Montréal, CHU Sainte-Justine, and the Montreal Heart Institute, institutions that set the standard for clinical rigour in Canada.
Growth roadmap
A Funded Path to
Commercial Scale,
Pharma Revenue, and Global Expansion
Each milestone builds on the last, regulatory foundation, then commercial traction, then high-margin pharma data revenue, then international scale. Every phase is sequenced, capital-efficient, and accountable to defined operational outcomes.
Regulatory & IP
Health Canada SaMD Class II approval secured. Patents granted in Canada and the US. Product validated across three therapeutic vert
Clinical Validation at Scale
Active deployments across pain management, women’s health, and mental health. Ecosystem of leading Canadian academic medical centres established.
Commercial Sales
Convert pilot sites into paid deployments. Recurring SaaS contracts and a built-out commercial team drive category ownership in pain, women’s health, and mental health.
Pharma Data Revenue
Convert pharma pipeline into structured RWE licensing agreements. Higher-margin recurring revenue layered on top of clinical SaaS base.
US & EU Expansion
FDA pathway, EU MDR alignment, and commercial entry into the US and European clinical markets. Strategic optionality at category-leader scale.
USE OF FUNDS
Where the Series A Goes
Our Series A capital is allocated across four strategic priorities to accelerate growth, deepen our platform, and capture the market opportunity over the next 18–24 months.
End-to-End Encrypted
20% — Platform & R&D
Expand engineering, accelerate the product roadmap, harden platform infrastructure and security, and deepen AI/ML capabilities that widen our competitive moat.
Go-to-Market
55% — Sales & Marketing
Build out the commercial engine — AEs, SDRs, sales engineering, customer success — scale demand generation, and expand across verticals, geographies, and channel partnerships.
Team & Leadership
15% — Talent & Operations
Key executive hires (VP Sales, VP Marketing, Head of People), operational infrastructure built for scale, and investment in culture and long-term retention.
Strategic Reserve
10% — Working Capital
Working capital, legal and regulatory compliance (SOC 2 and industry certifications), plus a reserve for opportunistic partnerships or strategic tuck-in acquisitions.
Who We Partner With
Find Your
Partnership Model
Whether you’re a healthcare institution, pharmaceutical company, research body, or investor, there’s a structured path to partner with AppMed™.
Pharma & biotech
Pharmaceutical & Biotech Companies
Leverage AppMed™ as a longitudinal data layer for your therapeutic programs, enabling adherence monitoring, titration support, and structured PRO collection at scale.
Investment
Strategic Investors & VC Partners
Join AppMed™’s growth trajectory. We’re raising to accelerate commercial deployment, expand therapeutic modules, and deepen our clinical network across Canada and beyond.
Research & Academic
Research Institutions & Universities
Access a structured, consent-governed data environment for longitudinal clinical research. AppMed™ reduces data collection overhead and enables multi-site collaboration.
Clinical Partners
Healthcare Organizations & Hospitals
Deploy AppMed™ across your patient population to improve clinical outcomes, reduce unplanned visits, and generate structured real-world data, with full institutional data control.
Question and Answers
Everything You Need to
Partner With Confidence
Answers to the most common questions from clinical, pharmaceutical, research, and investment partners. Don’t see yours? Book a discovery call and we’ll walk you through it directly.
What does a typical partnership with AppMed™ cost?
Our pricing is structured around partnership type. Clinical pilots typically follow a per-patient, per-month SaaS model. Pharma partnerships are structured as data licensing agreements or co-development contracts. Research partnerships are tailored to grant structure and multi-site needs. We share detailed commercial terms during the discovery call once we understand your scope.
Who owns the clinical data collected through AppMed™?
Data ownership stays with the originating institution. AppMed™ operates as a Law 25-compliant data processor — hospitals and clinical partners retain full institutional control over their patient data. Aggregated, de-identified insights may be shared with pharma partners only under explicit data-sharing agreements approved by the data custodian.
How long does it take to go from signed contract to live clinical deployment?
Most clinical partners go live within 4 weeks of contract execution. Our onboarding process — legal, technical integration, clinician training — is purpose-built to compress what traditionally takes months. Pharma data programs and multi-site research studies may take 6–10 weeks depending on scope.
Is there a minimum pilot size or commitment?
Clinical pilots typically start at 50–100 enrolled patients over a 3–6 month period, which is the minimum threshold for generating statistically meaningful real-world evidence. We can scope smaller proof-of-concept engagements for academic research contexts.
What therapeutic areas does AppMed™ currently support?
AppMed™ has purpose-built modules for pain management, women’s health, and mental health, with active clinical deployments in each. The platform architecture is therapeutic-area agnostic, so new modules can be configured for additional indications as part of a co-development partnership.
Does AppMed™ integrate with existing hospital EHR or research systems?
AppMed™ is built for interoperability but is not pre-integrated out of the box. The platform is designed around open standards (HL7 FHIR, REST APIs) and is compatible with major EHR systems, REDCap, and common pharma data warehouses — meaning a minimal, scoped integration effort is required to connect with each partner’s local environment. Integration work is defined during the technical setup phase and handled collaboratively by our team alongside your IT and clinical informatics stakeholders, typically within our standard onboarding timeline.
What are AppMed™'s regulatory and compliance credentials?
AppMed™ is Health Canada-approved as a Class II Software as a Medical Device (SaMD), conforming to IEC 62304, IEC 62366, and ISO 14971 standards. We are fully Law 25 (Quebec) and PIPEDA compliant, with all data hosted on AWS Montréal in Canadian sovereign infrastructure. Our platform is audit-ready for clinical, institutional, and regulatory review.
How is patient privacy protected?
All data is encrypted in transit and at rest, hosted on AWS Montréal, and governed under Law 25 and PIPEDA. Patient identifiers are separated from clinical data through a tokenization layer, and access is strictly role-based with full audit logging. No patient data leaves Canadian sovereign infrastructure without explicit contractual and ethical approval.
Is AppMed™ available outside of Canada?
AppMed™ is currently deployed commercially in Canada, with Health Canada SaMD Class II approval. US and EU expansion is on our 2026+ roadmap and includes regulatory alignment with FDA and EMA frameworks. International partnership conversations are welcome now, with deployment contingent on regulatory milestones.
Get Started
Ready to Partner With AppMed™?
Whether you’re a clinical organization looking to deploy, a pharma partner seeking real-world evidence, or an investor exploring Canada’s most compelling digital health platform, let’s talk.
Responses within 48 hours · NDA available on request · Quebec-based team